AAN 2021 | A new era in the discovery of ALS treatments

AMX0035 has shown significant functional and survival benefits in adult people with amyotrophic lateral sclerosis (ALS). Sabrina Paganoni, MD, PhD, Massachusetts General Hospital, Harvard Medical School, Boston, MA, discusses the progress made in the ALS field with more investigational products being tested at a faster pace. Dr Paganoni highlights the results of the CENTAUR trial (NCT03127514, NCT03488524) and is convinced that we are at the beginning of a new era in the discovery of treatments for ALS. This interview took place during the American Academy of Neurology (AAN) 2021 Annual Meeting.